Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
VEGFR2: , , ,
Things You Should Know Avoid aspirin, ibuprofen, and naproxen for 2 weeks before the injection
Frontiers in Pharmacology / PMC review
For example, if you're exploring the nuances of cellular energy metabolism, you might need the precise control offered by injections
While NAD+ contributes to cell function, it does not have the same targeted immune-boosting effects